Worth reading
60In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
450000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise status of the 20th Series Stock Acquisition Rights issued through a third-party allotment (with provisions for adjustment of the exercise price)
Who receives how much
Number of shares delivered during the month: 450,000 shares (450,000 new shares and 0 treasury shares transferred)
EVO FUND (issued on 14 October 2025)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
Exercise ratio subject to exercise restrictions: 1.3% (450,000 shares / 33,543,560 shares)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise prices during the month: ¥55.00, ¥56.00, ¥57.00 and ¥58.00. Details of the adjustment provisions and the adjustment floor: not disclosed
Number of Stock Acquisition Rights
Total issued: 141,000; exercised during the month: 4,500; unexercised at the end of the preceding month: 36,620; unexercised at month-end: 32,120
Procedures under the Corporate Code of Conduct
Reports compliance with the exercise restrictions under Article 434 of the Listing Regulations. The exercise ratio subject to exercise restrictions was 1.3%.
Most recent equity financing
Timing 14 October 2025 / Type Issuance of the 20th Series Stock Acquisition Rights (with provisions for adjustment of the exercise price) and the 1st Series unsecured privately placed bonds / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status of the 20th Series Stock Acquisition Rights issued through a third-party allotment (with provisions for adjustment of the exercise price) |
| Number of shares to be issued or disposed of | Number of shares delivered during the month: 450,000 shares (450,000 new shares and 0 treasury shares transferred) |
| Intended allottee | EVO FUND (issued on 14 October 2025) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 1.3% (450,000 shares / 33,543,560 shares) |
| Total number of issued shares | 43,981,560 shares (as of the end of the month preceding the target month) → Not disclosed |
| Exercise price | Exercise prices during the month: ¥55.00, ¥56.00, ¥57.00 and ¥58.00. Details of the adjustment provisions and the adjustment floor: not disclosed |
| Number of Stock Acquisition Rights | Total issued: 141,000; exercised during the month: 4,500; unexercised at the end of the preceding month: 36,620; unexercised at month-end: 32,120 |
| Procedures under the Corporate Code of Conduct | Reports compliance with the exercise restrictions under Article 434 of the Listing Regulations. The exercise ratio subject to exercise restrictions was 1.3%. |
| Most recent equity financing | Timing 14 October 2025 / Type Issuance of the 20th Series Stock Acquisition Rights (with provisions for adjustment of the exercise price) and the 1st Series unsecured privately placed bonds / Amount Not disclosed |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status. No other reasons for exercise or use of proceeds are stated in this document.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.